Collects samples and health information from people with cancer for research
Collects tissue samples, scans and questionnaires from people with cancer for research.
Key facts
- Who runs it
- European Organisation for Research and Treatment of Cancer - EORTC
- Where
- Birmingham, Bodelwyddan, Cambridge, Cardiff, Coventry, Edinburgh, Glasgow, Hereford, Leeds, Liverpool, London, and Manchester, United KingdomSee the 13 sitesAlso in 19 other countries, 123 sites
- Trial code
- Registry title
- SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
- Status
- Recruiting
- People taking part
- 4,975 people, planned
- Started
- 3 May 2017
- Expected to end
- Oct 2031
- Type of study
- Observational, 5 groups
- Treatments tested
- RP-1828 IMMUcan
- RP-1759 AYA/TYA
- RP-1843 Arcagen
- RP-1920 BioRadon
- 2148 MRD
- Record updated
- 24 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 or older with a confirmed type of cancer. It collects tumor samples, images and questionnaires to support cancer research.
- Age
- 12 years or older
- Sex
- All sexes can join.
- Disease stage
- Cancer that has been confirmed under the microscope for selected tumor types.
Main reasons for not taking part
- Not enough good-quality tumor or other biological material
- Any psychological, family, social or geographical situation that could get in the way of following the study plan and follow-up visits
- No written informed consent
The registry criteria, word for word
Show all 6 criteriaShow less
Other criteria
- Patients with pathologically confirmed selected tumor types (at site or centrally)
- Mandatory availability of adequate human biological material (HBM)
- Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements
- Age ≥ 12 years
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Written informed consent according to applicable legal and ethical requirements
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
The criteria questions were written by an AI system from the criteria published for NCT02834884. Checked by software, not by a doctor.
- How old is the patient who may join a trial?
Where in United Kingdom
Also in 19 other countries, 123 sites
- University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical CentreBirmingham, United KingdomContact: EORTC HQTaking people
- Royal Orthopaedics Hospital, NHS TrustBirmingham, United KingdomContact: EORTC HQNo longer taking part
- Betsi Cadwaladr University Health Board - Glan Clwyd District General HospitalBodelwyddan, United KingdomContact: EORTC HQTaking people
- Cambridge University Hospital NHS - Addenbrookes HospitalCambridge, United KingdomContact: EORTC HQTaking people
- Velindre NHS Trust, Velindre Cancer CentreCardiff, United KingdomContact: EORTC HQTaking people
- University Hospitals Coventry and Warwickshire NHS Trust - University HospitalCoventry, United KingdomContact: EORTC HQTaking people
- NHS Lothian - Western General HospitalEdinburgh, United KingdomContact: EORTC HQTaking people
- NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General HospitalGlasgow, United KingdomContact: EORTC HQTaking people
- Hereford County HospitalHereford, United KingdomContact: EORTC HQTaking people
- Leeds Teaching Hospitals NHS Trust - St. James's University HospitalLeeds, United KingdomContact: EORTC HQTaking people
- The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - LiverpoolLiverpool, United KingdomContact: EORTC HQTaking people
- Royal Free HospitalLondon, United KingdomContact: EORTC HQTaking people
- The Christie NHS Foundation TrustManchester, United KingdomContact: EORTC HQTaking people
About the trial
What the trial wants to find out
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
The 5 groups in the trial
- RP-1828 IMMUcan (CLOSED for recruitment since August 2024)
The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary
Treatment: RP-1828 IMMUcan
- RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)
The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS
Treatment: RP-1759 AYA/TYA
- RP-1843 Arcagen (CLOSED for recruitment since November 2022)
This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population. Tumor types: all 10 EURACAN domains
Treatment: RP-1843 Arcagen
- RP-1920 BioRadon
The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon). Tumor type: Thorax
- 2148 MRD
The main objective of the 2148 Minimal Residual Disease Assessment project is to assess the potential of circulating tumor DNA (ctDNA) as a surrogate marker of recurrence by studying its positive predictive value (PPV). This will help determine how accurately ctDNA can predict cancer recurrence. Tumour types: Head and Neck, Melanoma
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
- Plain-language title
- Collects samples and health information from people with cancer for researchGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT02834884, who can take part
- Record updated
- 24 June 2026